CA2464947C - Polytherapie pour le traitement de maladie - Google Patents

Polytherapie pour le traitement de maladie Download PDF

Info

Publication number
CA2464947C
CA2464947C CA2464947A CA2464947A CA2464947C CA 2464947 C CA2464947 C CA 2464947C CA 2464947 A CA2464947 A CA 2464947A CA 2464947 A CA2464947 A CA 2464947A CA 2464947 C CA2464947 C CA 2464947C
Authority
CA
Canada
Prior art keywords
antigen
alt
chemotherapeutic drug
patient
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2464947A
Other languages
English (en)
Other versions
CA2464947A1 (fr
Inventor
Birgit C. Schultes
Christopher F. Nicodemus
Antoine Noujaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Quest Pharmatech Inc
Oncoquest Inc
Oncoquest Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmatech Inc, Oncoquest Inc, Oncoquest Pharmaceuticals Inc filed Critical Quest Pharmatech Inc
Publication of CA2464947A1 publication Critical patent/CA2464947A1/fr
Application granted granted Critical
Publication of CA2464947C publication Critical patent/CA2464947C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés permettant de traiter le cancer, qui consistent à administrer à un patient souffrant du cancer un anticorps monoclonal xénotypique et un produit chimiothérapeutique. L'invention concerne également un procédé permettant d'induire une réponse immunitaire de l'hôte chez un patient contre un antigène tumoral in vivo à épitopes multiples présent dans le sérum de l'hôte, ledit antigène ne déclenchant pas une réponse immunitaire de l'hôte, qui consiste à administrer au patient un produit chimiothérapeutique et une composition comportant un liant qui se lie spécifiquement à un premier épitope sur l'antigène et à permettre au liant de former une paire agent de liaison/antigène, la réponse immunitaire d'hôte étant déclenchée contre un second épitope sur l'antigène.
CA2464947A 2001-10-26 2002-10-28 Polytherapie pour le traitement de maladie Expired - Lifetime CA2464947C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33924001P 2001-10-26 2001-10-26
US60/339,240 2001-10-26
PCT/IB2002/005794 WO2003034977A2 (fr) 2001-10-26 2002-10-28 Polytherapie pour le traitement de maladie

Publications (2)

Publication Number Publication Date
CA2464947A1 CA2464947A1 (fr) 2003-05-01
CA2464947C true CA2464947C (fr) 2012-05-22

Family

ID=23328122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2464947A Expired - Lifetime CA2464947C (fr) 2001-10-26 2002-10-28 Polytherapie pour le traitement de maladie

Country Status (9)

Country Link
AT (1) AT500649A1 (fr)
AU (1) AU2002358246B2 (fr)
CA (1) CA2464947C (fr)
CH (1) CH696871A5 (fr)
DE (1) DE10297379T5 (fr)
ES (1) ES2304264A1 (fr)
GB (1) GB2397018B (fr)
NO (1) NO20042166L (fr)
WO (1) WO2003034977A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2008091643A2 (fr) * 2007-01-23 2008-07-31 Altarex Medical Corp. Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858361A (en) * 1993-05-27 1999-01-12 Wagner; Uwe Monoclonal anti-idiotypic anti-CA125 antibodies and pharmaceutical compositions containing them
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
CA2376596C (fr) * 1999-06-25 2009-10-06 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
DE69934259T2 (de) * 1999-07-23 2007-05-31 Glaxo Group Ltd., Greenford Kombination von einem Anti-Ep-CAM-Antikörper mit einem chemotherapeutischen Mittel
ATE290879T1 (de) * 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
PT1254374E (pt) * 2000-02-08 2007-07-20 Altarex Medical Corp Método para diagnosticar a eficácia de uma terapia com anticorpos xenotípicos
CA2441393A1 (fr) * 2001-03-21 2002-10-03 Altarex Corp. Compositions therapeutiques permettant de modifier la reponse immunitaire

Also Published As

Publication number Publication date
ES2304264A1 (es) 2008-10-01
GB2397018A (en) 2004-07-14
GB2397018B (en) 2006-05-31
NO20042166L (no) 2004-05-25
AT500649A1 (de) 2006-02-15
AU2002358246B2 (en) 2008-02-28
CH696871A5 (de) 2008-01-15
WO2003034977A3 (fr) 2004-05-27
GB0409191D0 (en) 2004-05-26
CA2464947A1 (fr) 2003-05-01
DE10297379T5 (de) 2004-10-14
WO2003034977A2 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
KR102470294B1 (ko) 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
US20080311127A1 (en) Combination therapy for treating disease
CN101686971B (zh) 用于治疗多发性骨髓瘤的药物产品及其用途
ES2563439T5 (es) Medios y métodos para tratar LDCBG
WO2019072220A1 (fr) Utilisation d'un anticorps pd-1 combiné à un régulateur épigénétique dans la préparation d'un médicament pour le traitement de tumeurs
CN107614530A (zh) 用于多发性骨髓瘤（mm）的治疗
US8038994B2 (en) Combination therapy for treating disease
CN114423453A (zh) 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
CN101594877A (zh) 同时的化学疗法和免疫疗法
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
WO2008091643A2 (fr) Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie
CA2464947C (fr) Polytherapie pour le traitement de maladie
KR20110101134A (ko) 수지상 세포를 표적으로 하는 조성물
US20100008980A1 (en) Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer
KR20070086663A (ko) 암 백신 보조제로서 알파 티모신 펩티드류
AU2002358246A1 (en) Combination therapy for treating disease
US20250145693A1 (en) Herv-k antibody, cell, vaccine, and drug therapeutics
AU2014296038A1 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
Gilewski et al. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel
WO2026052074A1 (fr) Combinaison pharmaceutique comprenant un conjugué anticorps-médicament et un inhibiteur de point de contrôle immunitaire, et son application
WO2026061538A1 (fr) Anticorps bispécifique anti-pd-l1 et anti-4-1bb pour le traitement de tumeurs malignes, et combinaison pharmaceutique de celui-ci
NZ719768B2 (en) Means and methods for treating dlbcl

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221028